Ipilimumab: observed
99 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingNCT07786792Report a problem
- First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)RecruitingNCT07679061Report a problem
- Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)RecruitingNCT07394062Report a problem
- First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)RecruitingNCT07190677Report a problem
- Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentRecruitingNCT07147101Report a problem
- Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenRecruitingNCT07061379Report a problem
- Observational Study of Patients with Advanced Melanoma (skin Cancer) to Assess If IOpener®-melanoma Test Can Predict Response to Immunotherapy.RecruitingNCT06784778Report a problem
- Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant AppRecruitingNCT06675643Report a problem
- Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma ManagementRecruitingNCT06627595Report a problem
- Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint InhibitorsRecruitingNCT05649683Not applicableReport a problem
- International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
- Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingNCT05139706Report a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNCT04659343Report a problem
- Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab MonotherapyRecruitingNCT04605146Not applicableReport a problem
- JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingNCT04294771Report a problem
- Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationNCT04291755Report a problem
- Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingNCT04107168Report a problem
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedNCT05363072Results postedReport a problem
- Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)CompletedNCT03963518Results postedReport a problem
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results postedReport a problem
- Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or MelanomaTerminatedNCT00685750Not applicableResults postedReport a problem
- First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingNCT07852884Report a problem
- Pharmacokinetic Study of Therapeutic Plasma ExchangeWithdrawnNCT07756242Report a problem
- Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in PolandCompletedNCT07526961Report a problem
- IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaCompletedNCT07436390Not applicableReport a problem
- Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant MelanomaActive, not recruitingNCT07428252Not applicableReport a problem
- Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center AnalysisCompletedNCT07256184Report a problem
- Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%CompletedNCT07215962Report a problem
- Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabCompletedNCT07091695Report a problem
- Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron DatabaseCompletedNCT07079644Report a problem
- Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyCompletedNCT07024862Report a problem
- A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint InhibitorsActive, not recruitingNCT06630429Report a problem
- A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06487156Report a problem
- Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsCompletedNCT06345183Report a problem
- A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With MelanomaCompletedNCT06163170Report a problem
- EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem
- Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05714371Report a problem
- Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNCT05611229Report a problem
- A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung CancerCompletedNCT05599685Report a problem
- A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)CompletedNCT05324436Report a problem
- Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)CompletedNCT05308966Report a problem
- A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanActive, not recruitingNCT05161325Report a problem
- Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint InhibitorsCompletedNCT04898751Report a problem
- The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)SuspendedNCT04866810Not applicableReport a problem
- Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid TumorsStatus unknownNCT04860076Report a problem
- A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04794010Report a problem
- A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)Active, not recruitingNCT04196452Report a problem
- Polish Microbiome MapStatus unknownNCT04169867Report a problem
- Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064Report a problem
- AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.Status unknownNCT04145232Report a problem
- BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsStatus unknownNCT04136470Report a problem
- A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in JapanCompletedNCT04043975Report a problem
- ImmunoPET With an Anti-CD8 Imaging AgentActive, not recruitingNCT04029181Phase 1/2Report a problem
- Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)CompletedNCT03868046Report a problem
- A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USCompletedNCT03732560Report a problem
- A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.CompletedNCT03695835Report a problem
- INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell CarcinomaTerminatedNCT03692338Not applicableReport a problem
- A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has SpreadCompletedNCT03663946Report a problem
- 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCCompletedNCT03564197Not applicableReport a problem
- Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReActionCompletedNCT03492242Report a problem
- An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and GliomasNo longer availableNCT03460782Report a problem
- Improved Therapy Response Assessment in Metastatic Brain TumorsActive, not recruitingNCT03458455Report a problem
- Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerCompletedNCT03455452Report a problem
- Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint InhibitionCompletedNCT03453892Report a problem
- Long Term Quality of Life in Melanoma Patients in NetherlandsCompletedNCT03450876Report a problem
- Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination TherapyCompletedNCT03438279Report a problem
- Biomarkers of Immune-Related ToxicityActive, not recruitingNCT03409016Report a problem
- Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse ReactionsCompletedNCT03387540Report a problem
- TNF in Melanoma Patients Treated With ImmunotherapyCompletedNCT03348891Not applicableReport a problem
- Study of Adverse Renal Effects of Immune Checkpoints InhibitorsCompletedNCT03316417Report a problem
- Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic MelanomaCompletedNCT03225365Not applicableReport a problem
- A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanCompletedNCT03165422Report a problem
- Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has SpreadCompletedNCT03165409Report a problem
- Immune Checkpoint Inhibitors and Pre-existing Autoimmune DiseasesCompletedNCT03140137Report a problem
- Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyCompletedNCT02990611Report a problem
- Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyCompletedNCT02940639Report a problem
- IL2 Imaging in Metastatic MelanomaTerminatedNCT02922283Not applicableReport a problem
- Yervoy Pregnancy Surveillance StudyWithdrawnNCT02854488Report a problem
- GI Complications in Cancer Immunotherapy PatientsStatus unknownNCT02784366Report a problem
- Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyCompletedNCT02780089Report a problem
- An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or OpdivoWithdrawnNCT02763761Phase 2Report a problem
- Ipilimumab-induced Lung Toxicity: Observational StudyCompletedNCT02755233Report a problem
- Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune DiseasesCompletedNCT02739386Report a problem
- Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant MelanomaCompletedNCT02717364Report a problem
- RATIO: Rational Approach To Immuno-OncologyCompletedNCT02700971Not applicableReport a problem
- Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.CompletedNCT02600143Report a problem
- Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of ImmunotherapyStatus unknownNCT02581228Report a problem
- PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced MelanomaCompletedNCT02492815Report a problem
- Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation TherapyCompletedNCT02449837Report a problem
- Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in TaiwanCompletedNCT02402699Report a problem
- YERVOY® Risk Minimization Tool Effectiveness Evaluation SurveyCompletedNCT02224768Report a problem
- Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaNo longer availableNCT02186249Report a problem
- Ipilimumab 12-month Intensive Pharmacovigilance ProtocolCompletedNCT02050594Report a problem
- Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab TherapyCompletedNCT01789827Early Phase 1Report a problem
- Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related ToxicitiesTerminatedNCT01758575Report a problem
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic MelanomaCompletedNCT01511913Report a problem
- Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without SargramostimCompletedNCT01489423Report a problem
- Long-term Data Collection for Subjects in MDX-010 StudiesCompletedNCT00928031Report a problem
- Compassionate Use Trial for Unresectable Melanoma With IpilimumabNo longer availableNCT00495066Report a problem